Cepheid sees FY13 non-GAAP EPS 41c-46c, consensus 12c Sees FY13 revenue $375M-$385M, consensus $396.52M. Sees FY13net income to range from a net loss of (5c)-1c. Expected non-GAAP net income excludes approximately $29M related to stock compensation expense and approximately $4M related to the amortization of acquired intangibles. The fully diluted share count for the year is expected to be approximately 72M, except in the event of a GAAP loss where the share count would be approximately 67M shares.
Cepheid receives FDA emergency use authorization for Xpert Ebola diagnostic test Cepheid announced it has received Emergency Use Authorization from the FDA for Xpert Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours. The test runs on the Cepheid GeneXpert Systems. Xpert Ebola has been authorized by FDA under an Emergency Use Authorization for use by CLIA moderate and high complexity laboratories or similarly qualified non-U.S. laboratories. The test will begin shipping in April. Cepheid's Xpert Ebola has not been FDA cleared or approved, but will remain available in the U.S. as an EUA product as long as the declared emergency remains in effect or it ceases to be authorized by FDA.